HISTORY
In 1974, Prince and coworkers at the New York Blood Center reported that of 204 cardiovascular surgery patients followed prospectively, 51 patients (25%) developed posttransfusion hepatitis (294) . In 36 patients (18% of all patients and 71% of those with posttransfusion hepatitis), this was not caused by the hepatitis B virus (HBV) (294) . They concluded "that a large proportion of long-incubation post-transfusion hepatitis is unrelated to hepatitis B, and that control of post-transfusion hepatitis will require identification of a hepatitis virus(es) type C." Similarly, neither hepatitis A nor hepatitis B accounted for the posttransfusion hepatitis in a group of cardiac surgery patients monitored prospectively at the National Institutes of Health (90) . A (214) . Fax: (214) 648-5678. the diagnosis was one of exclusion (13) . In 1989, 15 years after the first suggestion that hepatitis C existed, a molecular biological approach was successful where many other techniques had failed and the hepatitis C virus (HCV) was cloned (59, 180). The virus responsible for most posttransfusion hepatitis, and at least a large proportion of sporadic or community-acquired non-A, non-B hepatitis, has thus been identified (12, 334) . VIROLOGY HCV was isolated and cloned by using a recombinant immunoscreening approach (59). Human factor VIII concentrate that transmitted non-A, non-B hepatitis was inoculated serially into chimpanzees to obtain an infectious plasma pool of .106 chimp infectious units per ml. Nucleic acids extracted from a crude viral pellet were used to generate a cDNA library that was screened with sera from a patient with posttransfusion hepatitis. A single positive plaque, 5-1-1, was isolated after -106 recombinant clones were screened. This positive plaque contained a 155- 81 . A series of experiments demonstrated that the cDNA hybridized to RNA from infected chimpanzee liver and serum but not to RNA from uninfected liver or to DNA from infected liver. The complete nucleotide sequence of the RNA genome of the original HCV isolate was then determined from overlapping clones. Thus, without specific knowledge of the type of virus involved, viral nucleic acid was cloned from infectious plasma samples.
Classification
The hepatitis C virion is small (30 to 34 nm) and enveloped and has a single-stranded, positive-sense RNA genome. Icosahedron-shaped particles of 33-nm average diameter recovered from HCV-infected plasma (360) may represent intact virions. A lipid envelope is suggested by the chloroform sensitivity of infectious material (30) and by changes in buoyant density with detergent treatment (155, 255) . Physicochemical studies indicate that HCV circulates in two forms, consistent with intact virions and nucleocapsids lacking the host-derived lipid envelope (155) . Besides lipids, there are exposed sugar moieties on the surface of hepatitis C virions, similar to those on hepatitis B virions (326) . There is a single, large, open reading frame that is predicted to encode a viral polyprotein precursor of -3,000 amino acids (3, 010 in the prototypic U.S. strain HCV-1; 3,011 in the Japanese strain HCV-J1 and other Japanese isolates) (60, 161) . The structure and organization of HCV most closely resemble those of flaviviruses and pestiviruses. The polyproteins from each of the viruses contain N-terminal structural domains encoding nucleocapsid and glycosylated envelope proteins, followed by nonstructural domains encoding processing and replicative proteins. Whereas the primary sequence of HCV shares little overall identity with that of individual flaviviruses and pestiviruses, the sequence upstream (5') of the large open reading frame is similar to that of animal pestiviruses. In addition, sections of the polyprotein have amino acid sequence similarities to animal pestiviruses, plant potyviruses, and human flaviviruses (60, 161) . The protein processing of HCV is most similar to that of pestiviruses (225) . The nucleotide, amino acid, and organizational similarities to the genera Pestivirus and Flavivirus of the family Flaviviridae have resulted in the proposal that HCV belongs to a separate genus of the family.
Viral Replication
The HCV genome is a positive-sense, single-stranded RNA. Both genomic (plus-strand) and replicative (minus-strand) forms are detected in infected liver tissue by PCR (98, 362) and in situ hybridization (15) and, by some investigators, in serum and peripheral blood mononuclear cells (98, 256, 391) . Detection of replicative forms in serum and peripheral blood mononuclear cells may be a PCR artifact (241) since only positivestrand RNA was detected following strand-specific reverse transcription of serum nucleic acids (318) . In chimpanzees, HCV RNA was detected in the cytoplasm of most hepatocytes by in situ hybridization 2 days after inoculation with HCVinfected serum (265) and was present in the serum by 3 to 7 days (2, 20, 88, 343, 344) . Hepatocyte HCV RNA remained detectable during the period of biochemical hepatitis, evidenced by abnormally elevated hepatic aminotransferase levels (265) . There was no apparent correlation between detectable intrahepatic HCV RNA and hepatocyte necrosis, suggesting that the virus may not be directly cytopathic. 
Viral Proteins
Although the virus has not been cultured, expression of viral sequences in a variety of systems has permitted tentative identification of many of the proteins encoded by the single open reading frame, including nucleocapsid (core [C]), envelope, and nonstructural proteins potentially involved in viral replication (Table 1) . Currently, it appears that three putative viral structural proteins, the core protein p16-22 (encoded in the C region) and two envelope glycoproteins, gp33-35 (El region) and gp7O-72 (E2/NS1 region), are processed by cellular signal peptidase cleavage of the polyprotein (Fig. 1) . In mammalian expression studies, the core protein, which has RNA binding activity (324) , was initially cytoplasmic (335, 341) and localized to the endoplasmic reticulum (324, 335) but was targeted to the nucleus by 6 days (341), whereas transport to a nuclear localization was observed earlier in insect cells (186) . When both El and E2 were expressed in insect cells, using a baculovirus expression system, or in mammalian cells with a recombinant vaccinia virus vector system, the El and E2 proteins were glycosylated and formed a complex (186, 303) . Purified E1-E2 complexes were recognized at high frequency by sera from HCV-infected persons (213, 303 Two virus-encoded proteinases are required for additional processing of the polyprotein. A zinc-dependent metalloproteinase activity (131), encoded by the NS2-NS3 region, is essential for cleavage at the NS2-NS3 boundary in trans (115) . A virus-encoded serine protease activity, located in the Nterminal portion of the nonstructural protein p70 from the NS3 region (80, 114) , apparently cleaves the NS3-NS4 boundary in cis (370) and the NS4-NS5 boundary, as well as internal sites in the NS4 and NS5 regions (NS4A-NS4B, NSSA-NS5B) in trans (80, 114, 370) . A C-terminal 33-amino acid sequence of the NS4A protein is required for some cleavages (85) , and this peptide sequence can activate the NS3 protease in trans (85) . By analogy with other members of the Flaviviridae, the nonstructural proteins are considered likely to be involved in viral replication. The NS3-encoded protein p70 has polynucleotidestimulated nucleoside triphosphatase activity (358) and putative RNA helicase activity in addition to serine protease activity. The NS5 region bears sequence similarity to other RNA polymerases (138) ; however, the exact functions of NS4 and NS5 proteins in the viral replication complex have not been elucidated.
SEQUENCE DIVERSITY
The ability to sequence specific areas of the HCV genome has allowed comparison of isolates from different individuals (Table 1) (60, 161) . On the basis of sequence analysis, there exist at least six major genotypes (genotypes 1 to 6), with two or more related subtypes (e.g., subtypes la, lb, and lc) within the major genotypes (354) . Although there is no standard genotype nomenclature at present, published correspondence suggests that the classification of Simmonds et al. (352) has been accepted by many investigators (351) . The precise implications of finding a particular genotype in any individual person are not yet elucidated, although ongoing mutation may be important in immune escape mechanisms (see next section). Furthermore, viral genotype and viral titer affect responsiveness to therapy with interferon (see below). Thus far, however, neither genotype nor viral titer has been unequivocally linked to disease progression (411) . Individuals can be coinfected with different genotypes (156) , particularly if they have experienced multiple exposures to HCV infection (353) . In one patient, genotyping permitted diagnosis of superinfection with one genotype in a patient chronically infected with a different genotype (156) .
There is an overall sequence similarity of -70 to 80% between the major genotypes of HCV (31; see also Table 1 ). The 5'-untranslated region contains the highest degree of sequence conservation, with -90% similarity overall (40, 193) ; however, the region consists of highly conserved domains interspersed with variable domains (40) . In other viruses, similar conserved 5'-untranslated regions have regulatory importance in replication of the viral genome or expression of viral genes. Elements in the 5'-untranslated region of genomic length HCV RNA that repress translation have been described (413) . Such elements may not be present in subgenomic length HCV RNA species (125) , thereby potentially allowing efficient translation and expression of viral genes.
Other regions of the HCV genome demonstrate greater degrees of diversity than the 5'-untranslated region (41, 351, 352, 354) . The core region is relatively well conserved, with nucleotide sequence similarity ranging from 81% (maximum diversity) to 88% (minimum diversity) between isolates of different genotypes (354) . The El and NS5 regions are less well conserved. Thus, isolates from different genotypes exhibit 53 to 69% sequence similarity in the El region and 56 to 72% in the NS5 region (354) . Within a specific genotype, subtype nucleotide sequence similarity is higher, ranging from 88 to 93% (core), 68 to 79% (El), and 75 to 86% (NS5 region) (354) .
Within a subtype, sequence similarity among isolates ranges between 88 and 99% in the core, El, and NS5 regions (354) .
Sequence data from other major areas of the genome are less extensive, except for the amino-terminal end of E2/NS1, which constitutes a hypervariable region. A segment of 28 amino acids in this region demonstrates more than 50% variation in different isolates. This hypervariable region, which includes <1% of the total amino acids in the polyprotein, contained 8 of the 44 amino acid substitutions observed in an experimentally infected chimpanzee over 8 years (277) . Even more striking, 9 of 13 amino acids in the E2/NS1 hypervariable region were changed in strain HCV-H when compared over a 13-year period in patient H (272) . The average mutation rate for the entire HCV genome has been calculated by comparing the sequence of the chimpanzee and HCV-H isolates obtained at different times. Rates of -1.4 x 10-3 and -1.9 x 10-3 base substitutions per nucleotide per year have been predicted (272, 277) . The mutation rate of most RNA viruses ranges from 10-1 to 10' substitutions per site per year, considered to be a reflection of the lack of proofreading ability of the RNAdependent RNA polymerases. Like other RNA viruses, HCV genomes in a single patient can be a mixed population (231, 257) , with a dominant sequence accounting for the majority of isolates. Other variants, present in minor proportions, then have the potential to become dominant if selection pressures are applied.
IMMUNOLOGIC RESPONSE TO HCV INFECTION
The extremely high rate of amino acid change in the hypervariable region of the E2/NS1 segment suggests that functional and structural constraints on the encoded protein are low, as predicted by analysis of the region (363, 397) . In the analogous segment of flaviviruses (NS1) and pestiviruses (E2), antigenically distinct variants are favored by selective immune pressures. A similar immune selection of HCV variants is observed (159, 342, 363, 397) . Clinically, changes in the hypervariable region may be silent (178, 261) or associated with distinct episodes of hepatitis (181, 319, 397) . Antibodies that prevent initiation of replication in vitro, and therefore have the potential to function as neutralizing antibodies in vivo, have been detected (342) . Sequence divergence over time resulted in the emergence of neutralization-resistant variants (342) . Immune selection of variants to escape from neutralizing antibodies is also suggested by the observation that the HCV hypervariable region in a patient with agammaglobulinemia showed no mutations over a 2.5-year period (179) . Together, these findings support the hypothesis that HCV sequence variation contributes to the failure of the immune response to clear the infection and develop protective immunity.
The immunologic reaction to HCV infection also includes cell-mediated responses. HCV-specific cytotoxic T lymphocytes have been detected in the livers of chimpanzees with acute and chronic infection (82) and in chronically infected patients (174, 175, 348) . Both core (nucleocapsid) and envelope proteins are recognized (174, 348) . Cytotoxic T cells that recognize the nucleocapsid protein can also be generated in vitro (163 (87) . Reinfection of the chimpanzees, not reactivation of previously occult virus, was demonstrated by PCR sequencing of the virus strain after inoculation (87) . A similar sequence of events may explain multiple episodes of hepatitis in polytransfused individuals (183) . If the responses of humans are similar to those of chimpanzees, then clearance of HCV from the blood and liver is not associated with protective immunity.
DETECTION OF INFECTION
Prevention of posttransfusion hepatitis C by identifying blood donor specimens capable of transmitting the virus to recipients was a major goal once the virus was isolated. Antibodies that recognize HCV protein epitopes have been detected in blood donor specimens and used to identify patients with HCV infection. The original fusion protein, expressed in yeasts, consisted of 363 virus-encoded amino acids from the NS4 region and was used in the first-generation enzyme-linked immunosorbent assay (EIA-1) for the detection of antibodies to HCV epitopes (Fig. 2) . This assay was able to identify HCV in the majority of transfusion recipients developing posttransfusion non-A, non-B hepatitis (9, 382) . In addition, donors implicated in the transmission of non-A, non-B hepatitis were also identified (9, 382) . Clearly, some donors and recipients were negative for HCV infection by the first-generation assay (9, 382) . Furthermore, although many patients with chronic hepatitis C had antibodies that reacted with the C100-3 amino acid sequence, a proportion remained negative. The sensitivity of first-generation assays was dependent on the population being studied, being greater (80 to 90%) in persons with parenteral risk factors and elevated hepatic aminotransferase levels suggesting chronic hepatitis (32) and lower (-60%) in volunteer blood donors (395) . False-negative results with the first-generation assay were, in part, explained by sequence variation (243, 259) . Antibody positivity was also delayed when only the C100-3 sequence was used for antigen expression, with seroconversion occurring 2 to 26 weeks after the onset of hepatitis (380) , decreasing the usefulness of the first-generation assay in the diagnosis of acute hepatitis C. The first-generation assay, therefore, lacked sensitivity, particularly for early recognition of acute disease.
The initial assays were also lacking in specificity. Thus, in one study, 44 of 14,068 blood donors were positive by EIA-1; however, 29 of 44 serum samples were negative by confirmatory recombinant immunoblot assay (168) . Sera with antibodies that cross-reacted with superoxide dismutase, the fusion partner used for expression of viral sequences in yeasts, accounted for some of the lack of specificity and were identified in a recombinant immunoblot assay (first generation). False-positive results with antibody assays for HCV infection have also been associated with stored and/or "aged" sera (212) , sera from tropical communities (369) , and following influenza vaccination (219) . Hyperglobulinemia and rheumatoid factor (anti-immunoglobulin) also resulted in false-positive anti-HCV tests with first-generation assays (239, 332) . Attempts to improve both the specificity of blood donor screening and the sensitivity of detecting patients with HCV infection have resulted in a number of newer assays.
Second-and Third-Generation Assays
Other putative HCV proteins were examined for potential capacity to detect acute infection earlier and chronic infection with greater reliability. Linear peptides encoded in the putative nucleocapsid or core (C) region and the E2/NS1 region are recognized by human antibodies (57, 264, 321, 397) . Within each region, some sequences are recognized more commonly, suggesting that they are immunodominant (264, 321, 397) . In addition, serologically distinct responses to the putative core protein were demonstrated in patients with genotypically different viral isolates (218) . These antibodies recognized peptides encoded in a variable segment of the otherwise highly conserved region. In comparison with first-generation assays, synthetic peptides from the core region allowed earlier detection of HCV infection (a mean of 6 weeks after the onset versus a mean of 9 weeks) (380) . HCV RNA is also more likely to be detected in samples containing antibodies to core sequences (62) .
Sequences from the NS3 region (C33c) appear to be immunogenic in the majority of those with HCV infection (56). Furthermore, the C200 polypeptide that includes C33c, C100-3, and the intervening region (NS3 and NS4 sequences) was the most effective at blocking labeled antibody binding to HCV antigen(s) in hepatocytes (176) . These peptide sequences have been included in the second-generation ETA (EIA-2) and immunoblot assays to provide multiple separate antigenic epitopes ( Fig. 2) (56) . Inclusion of native envelope protein antigens may increase sensitivity and permit earlier detection of seroconversion in future assays (213) . Thus, sera react against El and E2 antigens expressed in yeasts less commonly than when expressed in mammalian cell systems, in which glycosylation and complex formation can occur (213) .
Second-generation assays have increased sensitivity (99%) in identifying blood donors with hepatitis C viremia (395) (32, 195, 295) . Furthermore, HCV antibodies were detected with 100% sensitivity in 184 hemophiliacs and 31 other patients with chronic hepatitis and HCV viremia (32) . In addition, improved specificity has also been demonstrated by some investigators. Fewer ETA-positive blood donors were negative on confirmatory assay: 22 of 70 (31%) by EIA-2 compared with 29 of 44 (66%) on EIA-1 screening of 14,068 donors (168) . Overall, the specificity of current assays is >99.5% (195, 327) . Crossreactivity to the superoxide dismutase fusion partner of C100-3 expressed in yeasts and to proteins in lysates of yeasts and Escherichia coli may be minimized by including these proteins in the diluting solutions, thereby preventing attachment of the nonspecific antibodies to the immobilized, specific proteins (295) . False-positive rates may remain high with sera collected in Africa, even when analyzed by second-generation assays (44) . New third-generation assays contain an additional antigen from the NS5 region. Improvement in sensitivity and/or specificity was not demonstrated in a study of French blood donors with evidence of hepatitis (elevated levels of the hepatic enzyme alanine aminotransferase [ALT] in serum) that compared second-and third-generation assays (228) .
The prevalence of anti-HCV reactivity (EIA-2) in the U.S. blood donor population is 0.37% (153 of 41, 250) December 1993 
The true prevalence of HCV infection may therefore be substantially higher than the 0.3 to 0.7% observed in blood donors.
Anti-HCV antibodies persist in the serum in most patients (12, 76) but may become undetectable spontaneously or following interferon therapy (12, 76, 325, 372, 417) . Thus, in a follow-up study of 81 patients who developed non-A, non-B hepatitis after receiving HCV-infected immune globulin, 52 of 56 (93%) were anti-HCV positive 6 to 12 months after infection and 45 of 65 (69%) were positive 9 to 10 years after infection (76) . Loss of antibody is more common in those who have resolving disease clinically (12, 76, 372) , but it is also observed in conjunction with development of immunocompromise from HIV infection (48, 213, 244, 302) . Loss of reactivity to only C100-3, the single antigen expressed in the initial assays, is more common than loss of reactivity to all antigens (325, 372) .
HCV RNA and Detection of Infection HCV sequences can be detected either by standard PCR amplification techniques, using conserved oligonucleotide primers followed by hybridization of a labeled probe to internal sequences, or by "nested" or two-stage PCR amplification with external and internal primers and visualization after gel (122, 154, 169, 237) , needle stick accidents (165, 254) , participation in ritual ceremonies, and use of folk remedies (16, 166) . Transplantation with organs from HCV-infected donors can transmit HCV (285, 286, 315) but does not always do so (390) . Thus, none of six recipients of kidneys from four anti-HCV-positive, HCV RNA-positive donors became infected, as evidenced by negative anti-HCV and no HCV RNA (390) . Perfusion of kidneys with subsequent removal of contaminating blood may explain the difference in transmission. Corneas, which are avascular, may not transmit hepatitis C either, since no HCV RNA was detected in corneas from HCV RNA-positive individuals (191) .
HCV infection has been prospectively identified in potential blood donors since the introduction of routine screening, which was in mid-1990 in the United States. Before the introduction of anti-HCV testing, elevated ALT levels and anti-hepatitis B core antibody positivity were used as surrogate markers for blood donations likely to transmit hepatitis. However, HCV infection and elevated aminotransferase levels are not synonymous in blood donors. ALT levels were monitored for 6 months and were repeatedly normal in 5 of 50 (10%) volunteer blood donors with HCV infection in one study (237) . Furthermore, although many blood donors with HCV infection may have elevated ALT levels, the converse is not true (158, 379) . Two U.S. studies have examined the incidence of HCV infection in blood donors with elevated ALT levels, suggesting the possibility of HCV infection (158, 379) . Anti-HCV antibodies were confirmed in only 17 of 100 and 11 of 101 donors, respectively (158, 379) . Furthermore, HCV RNA was detected in only 8 of 11 donors with anti-HCV antibodies and none of 89 seronegative donors (379) . Current screening assays, therefore, are both more sensitive and more specific than elevated ALT levels in identifying HCV-infected blood products, and their introduction has resulted in a further decrease in the rate of posttransfusion infection with HCV (19, 77, 268) .
Worldwide, injection drug use is probably the most common risk factor for HCV infection, with -80% seropositivity in this population in the United States (162, 242) . In pregnant women in Dallas, Tex., anti-HCV antibodies were positive in 23 of 1,005 (2.3%) when samples were screened by first-generation assays (27) . Injection drug use was reported by 10 In the Sentinel Counties Non-A, Non-B Hepatitis Study, specific questioning of patients with acute hepatitis C elicited the presence of parenteral risk factors in 59% and sexual or household contact with hepatitis in 6% (12) . An additional 28% were classified as having a nonparenteral risk factor since they had completed less than 12 years of schooling (Fig. 3) , a marker of "low socioeconomic level" and a finding previously shown to correlate with non-A, non-B hepatitis cases when compared with controls (10). In 7%, there were no identifiable risk factors (Fig. 3) . For comparison, in 24 patients with acute non-A, non-B hepatitis that was not hepatitis C (non-A, non-B, non-C), no risk factors were identified in 25% and only low socioeconomic level (i.e., nonparenteral risk factor) was identified in an additional 54%. Parenteral risk factors were less frequent in the non-C group (13%), although close contact was similar to those with HCV markers (8%). An investigation of acute non-A, non-B hepatitis in 50 consecutive patients in Dallas, Tex. (150) , identified parenteral risk factors in 25 of 34 patients with HCV infection but none in patients without hepatitis C.
Infection in Patients with Repeated Parenteral Exposure
Patients with bleeding disorders or chronic renal failure requiring dialysis are commonly and frequently exposed to blood and blood products. Many hemophiliacs are positive for anti-HCV antibodies. HCV reactivity is associated with both HBV and HIV infections in hemophiliacs (36, 223, 373 (373) . A recent prospective study demonstrated that solvent and detergent inactivation of chromatographic factor VIII concentrate was efficacious in preventing anti-HCV seroconversion in 31 patients treated with 41 different lots (230) . This approach or a similar viral inactivation process, together with screening donors for anti-HCV reactivity, should prevent transmission of HCV to hemophiliacs in the future.
Unlike factor VIII, intravenous immune globulin generally has not transmitted HCV (368) . Consistent with lack of infectivity, HCV RNA was not detected in immune globulin preparations despite the presence of anti-HCV (296, 320) . The processing of plasma pools for intravenous immune globulin preparations removes or inactivates HCV (23) . Thus, infusion of EIA-1-negative, pooled plasma into chimpanzees resulted in transmission of HCV (23) . In contrast, infusion with intravenous immune globulin prepared from the EIA-1-negative, pooled plasma did not transmit HCV. Unfortunately, some preparations of intravenous immune globulin have been implicated in transmission of hepatitis (14, 24, 201, 300, 405) , often with progressive disease developing in the recipients (24, 198 (412) ; apparently, any HCV RNA remaining in the immune globulin preparation is usually inactivated by other processing steps. The apparent outbreak of HCV infection linked to intravenous administration of immune globulin prepared from EIA-2-negative, pooled plasma (14) is of great concern. A number of theoretical explanations for HCV transmission have been proposed (14) . These include lack of a viral inactivation step, failure of quality control, and possible inability of normal processing to remove HCV due to high viral titer or lack of anti-HCV antibodies in the plasma pool.
Patients with renal disease on hemodialysis also have the potential to be continually exposed to infectious materials. The prevalence of markers for HCV infection varies widely, depending on geographic origin of the patients and the presence of other parenteral risk factors. In Japan, EIA-2 detected anti-HCV antibodies in 74 of 167 (44%) patients (273) .
Similarly, in the United States, 31 of 87 (36%) patients were positive by anti-HCV assays (second-generation immunoblot) (127) . Reactivity correlates with length of time on dialysis but not blood transfusion history or aminotransferase levels (127, 145) . In contrast, only 6 of 79 (8%) Belgian patients were positive for anti-HCV antibodies (EIA-2), with HCV RNA detected in 4 of 79 using nested primers from the 5' noncoding region (404) . Similarly, 28 of 340 (8%) Danish patients on hemodialysis were anti-HCV positive and 27 of 28 had HCV RNA detected (42) . Of anti-HCV-negative patients in this study, 7 of 38 (18%) with recently elevated aminotransferase levels and 1 of 16 (6%) with remotely elevated aminotransferase levels were also positive for HCV RNA. None of 36 patients with normal aminotransferase levels and negative for anti-HCV had HCV RNA detected. Altogether, therefore, an additional 8 hemodialysis patients (from 90 anti-HCV-negative patients tested) were infected with HCV, an estimated overall rate of 11% in the Danish hemodialysis population (42) . Inclusion of native envelope protein antigens in future assays may permit identification of HCV infection in hemodialysis patients (213) without resorting to measurements of HCV RNA. The findings that 67 to 96% of anti-HCV-positive dialysis patients have detectable HCV RNA (42, 49, 112, 290, 350, 404) and that serologic positivity correlates with length of time on dialysis suggest that limitation of anti-HCV patients to a particular dialysis station may be useful. However, one study considered the explanation to be nosocomial transmission of HCV by inapparent percutaneous route, since there was infection of dialysis patients at adjacent stations (146) . Also suggesting nosocomial spread of HCV, operating room equipment was considered to explain an apparent outbreak of HCV infection in four patients undergoing surgery on a single day (301) . Furthermore, in prospective studies of posttransfusion hepatitis rates, hospitalized control patients have developed non-A, non-B hepatitis without transfusions (1), suggesting that there are risk factors associated with transmission of infection in hospitals.
HCV infection is also encountered commonly in recipients of renal transplants (50, 187, 316) . In Hong Kong, 23 of 185 (12%) renal allograft recipients were infected with HCV. Anti-HCV antibodies were detected in 19 patients, whereas serum HCV RNA was present without antibody in 4 of the 23 patients (17%) (50). Infection was generally acquired before or at the time of transplantation, again suggesting that measures targeting the hemodialysis population were needed for effective prevention. Similar rates of infection were observed in the United States (187): 25 of 100 renal allograft recipients were infected with HCV before transplantation and 7 of the 25 (28%) were positive for HCV RNA without antibodies. Another six patients acquired HCV infection during the first year after transplantation. Clearly, transplant recipients and other patients will be at increased risk of HCV infection until all routes of transmission of HCV are identified.
Occupational Hazards Health care workers represent 2% of acute hepatitis C patients (329) and may have higher rates of chronic HCV infection than the general population. Thus, -2% (8 of 456) of dentists in New York, particularly oral surgeons (9%, 4 of 43), were anti-HCV positive by first-generation immunoblot, significantly more than the control population (0.14%, 1 of 723) (167) . The magnitude of the potential risk to health care providers was underscored in a study of the prevalence of seropositivity for HCV in emergency room patients of a large inner-city hospital, Johns Hopkins University Hospital (162) . Antibody to HCV (second-generation immunoblot) was present in 18% (458 of 2,523) of patients, with rates as high as 51% in some age-, sex-, and race-defined groups. Similar results have been reported from the Washington, D.C., Veterans Administration Medical Center, with 24% of 450 consecutive inpatients testing positive for anti-HCV by EIA-2 assays (333). Since needle stick exposure may lead to transmission of HCV in up to 10% of instances (infection in 7 of 68 with needle stick from HCV RNA-positive source in Japan) (254) , the potential risk of contracting hepatitis C is considerable. However, lower rates of transmission of HCV infection by needle stick accidents to health care workers have been observed in other institutions, 3 of 90 and 0 of 81 employees (128, 356) , and antibodies to HCV were found in only 7 of 943 (0.7%) health care workers at the Johns Hopkins University Hospital (367) , suggesting that occupational transmission is infrequent. Viral titer differences may explain the disparity. (210) , and 4 to 5% in homosexual men (210, 280) , all higher than in volunteer blood donors. The exclusion of subjects with a history of blood transfusion or injection drug use in the determination of prevalence rates in prostitutes, their clients, and homosexual men (210) decreases the likelihood of these risk factors being responsible for the increased seroprevalence.
Heterosexual spouses of anti-HCV-positive hemophiliacs have a low incidence of anti-HCV positivity in some studies (29, 84, 124) , with no evidence of transmission in other studies (34, 83) (open symbols, Fig. 4 ). Coinfection with HIV raises the likelihood of transmission (84), as does the presence of other HCV risk factors (124) . Similarly, when the anti-HCVpositive index cases were largely injection drug users rather than hemophiliacs, HCV positivity was lower in stable heterosexual partners (not themselves injection drug users) when the index case was HIV negative (2 of 49, 4%) than when the index case was HIV positive (9 of 98, 9%) (210). Higher rates of HCV infection in household contacts has been observed in studies from Taiwan, Japan, and Italy (solid symbols, Fig. 4) , with 15 to 28% of spouses positive for anti-HCV antibody (4, 43, 51, 135, 157, 279, 284) . HCV nucleotide sequences from two family members (one child and one spouse) in one study were significantly more homologous to the corresponding patient than to other HCV-infected persons (135) and were identical in three couples in another study (157) , suggesting the occurrence of familial transmission in some but not all cases.
Other practices, such as folk remedies with percutaneous exposure (166) , may explain the increased rate of household and spousal transmission in these areas. Alternatively, higher viral titers may lead to intrafamilial spread as well as to maternal-infant transmission (275) .
HCV RNA has generally not been found in body secretions Vertical transmission of HCV, although uncommon, has been well documented (144, 269, 275, 365, 399) . Chronic non-A, non-B hepatitis was observed in 2 of 13 live-born infants of 11 mothers with chronic non-A, non-B hepatitis (401) , suggesting the possibility of mother-to-child transmission. In eight infants born to mothers positive for both anti-HCV and HCV RNA, HCV RNA was either intermittently positive or positive in all samples of blood from infants up to 12 months of age (365) . HIV infection was present in three of the mothers but only one child. Anti-HCV antibody was initially detected in the infants but was absent from all samples of infants more than 5 months old, suggesting that the initial positive results reflected passive transfer of maternal antibody. Aminotransferase elevation was intermittent or absent in the infants. Thus, neither antibody status nor biochemical studies indicated infection with HCV. However, in additional studies assaying both anti-HCV positivity and HCV RNA, vertical transmission was not detected (0 of 47) (309, 317) or was infrequent (5 of 87, 6%) (184, 402) . The demonstration that maternal transmission of HCV infection in Japan was correlated with viral titers of .106 per ml (207, 275) , with no cases of vertical transmission at titers of <106 per ml (275) marker of HCV (12) . In four patients who were anti-HCV negative on commercial testing (one of these patients was HCV RNA negative; three were not tested), antibodies that recognized HCV antigen in liver were present (12) . These antibodies presumably recognize structural or other determinants not present on the linear peptide antigens used in ELAs. They blocked the binding of fluorescently labeled human IgG that is reactive with HCV antigens in frozen liver biopsy specimens from experimentally infected chimpanzees (176) . Similar blocking antibodies were also present in 19 of 19 anti-HCV-positive patients and 5 of 9 patients with HCV RNA but without anti-HCV reactivity. Thus, readily available tests were able to identify 88% of HCV-infected patients, whereas research assays were needed for the remaining 12%.
HCV and Acute Non-A, Non-B Hepatitis
The proportion of acute non-A, non-B hepatitis patients exhibiting HCV markers varies with the assay(s) used, geographic origin of the patients, and the risk factor profile of the selected patients (12, 100, 110, 299 ). The highest rates were observed in Italy with the combination of EIA-2 and immunoblot assays plus HCV RNA detection (110, 299, 372) . In Los Angeles patients with acute non-A, non-B hepatitis, anti-HCV positivity was higher in injection drug users (109 of 118, 92%) than in patients with "sporadic" infection (59 of 96, 61%) (100) . HCV infection is usually demonstrated in -90% of patients with posttransfusion hepatitis, but not 100%, even with the latest assays, as shown in Fig. 5 (91, 205, 322, 409) . HCV RNA could not be amplified from serum and/or hepatic tissues of patients with fulminant acute non-A, non-B hepatitis (91, 322, 409) . In contrast, HCV alone or coinfection of HCV together with other hepatitis viruses was observed in patients with fulminant hepatitis in Asia (61, 263, 410, 414) . Occasional cases of fulminant hepatitis in patients positive for anti-HCV antibodies have been reported from Europe and the United States, but they are rare (177, 205, 330 ). An exception is a recent preliminary report from the United States of HCV RNA detection in 9 of 15 (57%) patients with fulminant hepatitis of indeterminate etiology, of whom four were anti-HCV positive (389) . HCV RNA was also detected in two of seven patients with fulminant hepatitis B. HCV infection in this group of patients was associated with low socioeconomic level, and no patients had a history of parenteral risk factors (388) . Until a definitive test for recent or acute HCV infection is devised, the possibility remains that these patients were chronically infected with HCV and then developed fulminant hepatic failure from another etiologic agent. The data thus suggest that both sporadic and parenterally transmitted acute infection may be caused by an agent other than those already identified.
Symptoms gradually resolve in the majority of patients with acute HCV infection. Laboratory investigations, however, may be persistently abnormal for months or years. The percentage of patients with documented chronic hepatitis following acute hepatitis C is usually very high (64 to 88%; Fig. 6) (12, 110, 173 , 235, 393). Chronic hepatitis following acute posttransfusion hepatitis is no more common than that following sporadic or community-acquired disease when anti-HCV-positive cases are compared (12, 110, 173, 235) . When anti-HCV tests are nonreactive, chronic hepatitis is less common than when these tests are positive (Fig. 6 ).
Whether HCV infection is eradicated and/or inactivated in the 12 to 36% of patients with clinical resolution of acute hepatitis is undetermined. Of great concern, HCV RNA was detected in all 15 patients (intermittently in 2) with normal aminotransferase levels and clinically resolved hepatitis who were tested in the Sentinel Counties study 42 to 48 months after their acute illness (12) . Similarly, persistent viremia following biochemical resolution was observed in 10 patients with acute posttransfusion hepatitis (287) . In other studies, however, clinical and biochemical resolution was accompanied by clearance of the virus from serum in all but one of a total of 25 patients (111, 133, 299) . These data suggest that HCV infection may persist in some, but not all, patients when there is no evidence of clinical or biochemical disease. Persistent HCV RNA detection in serum, despite normalization of aminotransferase elevation, has also been observed following treatment with alpha interferon (152, 190, 325) . Whether HCV infection is actually eliminated in patients with undetectable HCV RNA in serum remains unanswered.
CHRONIC HEPATITIS
Evidence of HCV infection is found in 60 to 100% of patients with chronic hepatitis when other causes are excluded and EIA-2 screening tests are used (38, 118, 148, 260, 311) . Higher rates of HCV infection are observed in Japan and Mediterranean countries, and lower rates are seen in the United States and the United Kingdom. Measurement of HCV RNA by PCR does not substantially increase the number of patients demonstrated to have HCV infection. Thus, detection of HCV RNA in patients with chronic hepatitis, yet negative for anti-HCV antibodies by EIA-2 assays, is apparently uncommon (except in the immunosuppressed population), although there are few data to evaluate (55, 192, 260, 418) . In French alcoholics, HCV RNA was detected in one of five patients negative for anti-HCV antibodies (192) ; however, no clinical data regarding chronic hepatitis or possible immunosuppression from coinfection with HIV were provided. Of four Japanese patients negative for both anti-C100-3 and anti-HCV core (C22) who had chronic non-A, non-B liver disease (one with chronic hepatitis, one with cirrhosis, and two with cirrhosis and hepatocellular carcinoma), only one with chronic hepatitis was positive for HCV RNA by PCR (418) . Similarly, two Japanese patients (one with chronic hepatitis and one with cirrhosis) negative for anti-HCV antibodies (by EIA-2) were positive for HCV RNA by PCR (260) . Different primer sets were required for one patient, indicating sequence variability. Anti-HCV antibodies recognizing antigenic epitopes not represented in current assays may be present in such patients, thereby accounting for the negative result on testing with second-generation assays. In contrast to these isolated patients, 156 (91%) of 172 consecutive Italian patients with chronic non-A, non-B hepatitis had anti-HCV antibodies whereas 9% (26 of 172) did not; 86% (89 of 104) of anti-HCV-positive serum samples were HCV RNA positive, but none of the anti-HCV-negative serum samples contained HCV RNA (55).
In patients with chronic hepatitis and anti-HCV antibodies by EIA-2, HCV RNA is very frequently detected (211, 260) . In Hong Kong, 67 of 81 (83%) patients with anti-HCV antibodies (EIA-2) were viremic when two different primer sets (5' noncoding and NS4) were used for PCR amplification (211) .
Similarly, 201 of 224 (90%) Dutch patients who were anti-HCV positive by EIA-2 and had multiantigen positivity on immunoblot were viremic; 21 of 31 (68%) with C22 or C33c single-antigen positivity on immunoblot ("indeterminate") were also viremic (35) . In Japan, 98 of 100 patients with chronic non-A, non-B liver disease were positive for anti-HCV antibodies by EIA-2 and 100 of 100 were positive for HCV RNA by PCR (260) . Chronic HCV infection as an etiologic agent in chronic non-A, non-B liver disease can thus be readily identified in most patients with currently available secondgeneration assays.
HCV and Other Chronic Liver Diseases The potential role of HCV infection in the chronicity or progression of liver diseases considered secondary to other etiologic agents has also been examined. The proportion of patients with (ostensibly) other liver diseases, but having evidence of HCV infection, is generally highly related to the country of origin of the patient group. Anti-HCV antibodies were positive in 15 of 88 Italian patients with primary biliary cirrhosis (22) , for example, but were not detected in 31 British patients (239) . Italian patients with hereditary hemochromatosis also commonly manifested evidence of HCV infection (10 of 78, 13% anti-HCV and HCV RNA positive) and chronic hepatitis on liver biopsy (288) . The finding of anti-HCV antibodies in patients with alcoholic liver disease is also dependent on geographic origin (see below). In al-antitrypsin deficiency, liver involvement is variable and HCV infection may account for development of overt hepatic manifestations (297) . Among 53 patients with cirrhosis and either homozygous or heterozygous al-antitrypsin deficiency, anti-HCV antibodies (EIA-2) were detected in 62% (33 of 53) (297) . Markers of HCV infection were positive in only 4 of 78 (5%) patients with fatty liver, rather than cirrhosis, and either heterozygous or homozygous cl-antitrypsin deficiency. The data suggest that patients with significant liver disease and al-antitrypsin deficiency may have another etiopathologic factor in addition to the abnormality in al-antitrypsin.
Autoimmune Chronic Liver Disease
There is an especially complicated relationship between HCV infection and autoimmune chronic liver disease (reviewed in reference 306) . In Italy, anti-HCV antibodies found in patients with autoimmune chronic hepatitis on first-generation testing were generally confirmed reactive on secondgeneration assays (46, 200, 220) regardless of the type of autoimmunity. Additionally, antibody reactivity was often associated with HCV RNA positivity in Italian patients with autoimmune features (10 of 15 [67%], using a single primer set) (220) , indicating true infection. Japanese patients with autoimmune chronic hepatitis were also likely to be reactive on both first-and second-generation assays for anti-HCV antibodies, but HCV RNA was less often detected (5 of 26 [19%] , using nested primers from the 5' noncoding region) (266) . In contrast, Swedish and British patients with autoimmune chronic hepatitis had false-positive anti-HCV reactivity that correlated with disease activity and hyperglobulinemia (200, 239, 332) . Similarly, although serologic markers of HCV infection were found in 8 of 17 (47%) U.S. patients with autoimmune hepatitis, these were generally not confirmed by immunoblot (2 of 17 positive, 12%) or detection of HCV RNA (1 of 17, 6%) (101) .
The association between HCV and type 2 autoimmune chronic liver disease suggests a relationship other than a false-positive anti-HCV test or coexistence of both diseases (306) . In type 2 autoimmunity, antibodies to liver and kidney microsomes (anti-LKM) are present. Anti-LKM1 recognizes cytochrome P-4501ID6 (227) (105, 199, 216, 247) . This is particularly so in older patients, especially men, with low titers of anti-LKM1 antibodies (216) . Younger patients are more often negative for anti-HCV antibodies (200, 216) . Additionally, patients with HCV infection and anti-LKM, antibodies are also frequently positive for antibodies directed against a cross-reactive determinant expressed in liver, GOR. GOR antigen shares part of its amino acid sequence with the HCV core protein (136, 423) . Anti-GOR antibodies were found in 10 of 31 (32%) U.S. patients with chronic hepatitis C (189) . The (248) . The geographic distribution may therefore reflect differences in the major histocompatibility complex and the selection of specific peptides for presentation to autoreactive lymphocytes.
Alcoholic Liver Disease Early studies of U.S. patients with alcoholism demonstrated an increased frequency of anti-HCV positivity (27% by EIA-1) in those with clinical liver disease (245) . There was no such relationship for antibodies to hepatitis B. However, many of the reactive sera were negative by confirmatory immunoblot. The reported decreased survival in those patients with unconfirmed reactivity was unexplained (245) . Antibodies to HCV, found in up to 68% of selected Japanese patients with alcoholic liver disease, were associated with HCV RNA positivity and increased histopathologic damage (267) . Similar findings were made in a Spanish investigation (283) . In France, 22 of 62 (35%) patients with chronic alcoholism had anti-HCV antibodies (second-generation immunoblot) and HCV RNA was also detected in 18 of the 22 patients (262). Liver biopsies demonstrated only alcoholic liver disease in seven patients with viremia, but a mixed picture of virus-and alcohol-related pathologic lesions was observed in five patients. Infection with HCV may substantially increase the likelihood of significant liver disease in alcoholic patients. The finding that anti-HCV positivity in alcoholic patients could often be explained by a history of previous injection drug use (97, 314, 385) suggests the coexistence of two relatively common potential causes of chronic liver disease. Whether there is an interaction between the pathogenetic processes, however, is less clear.
Hepatitis B Coinfection
Because of shared epidemiology, coinfection with both HBV and HCV occurs. Evidence of coinfection with both B and C hepatitis viruses was observed in 16 of 148 (11%) patients monitored at the National Institutes of Health (96) . These patients were more likely to have cirrhosis and decompensated liver disease and have HIV infection, consistent with shared epidemiology. Retrospective analysis of patients prospectively monitored for posttransfusion hepatitis demonstrated that of 12 patients who developed hepatitis B, 5 were infected with HCV concurrently (249) . Coinfection with both viruses delayed the appearance of HBsAg, reduced the antigen concentration, and was associated with lower aminotransferase levels and a biphasic pattern of elevation. In Chinese patients with VOL. 7, 1994 on October 19, 2017 by guest http://cmr.asm.org/ Downloaded from chronic hepatitis B who underwent spontaneous clearance of HBsAg, markers of HCV infection (EIA-2) were found much more frequently (17 of 54, 31%) than in matched controls (9 of 152, 6%) who remained HBsAg positive (337) . Other investigators monitoring small numbers of patients have not observed any significant interaction between chronic HBV infection and HCV (393) .
A potential explanation for a decrease in HBsAg has been suggested by recent experimental studies (341) . Expression of HCV core gene sequences in a human hepatoma cell line interfered with and suppressed replication of hepatitis B and secretion of hepatitis B viral particles (341) . Furthermore, a reciprocal inverse pattern of viral interference was observed in 25 Italian patients chronically coinfected with both HCV and HBV (292) . When serum contained sufficient HBV DNA to be detected without PCR amplification (10 patients), HCV RNA was positive in only 1 patient (10%) whereas if HBV DNA was undetectable in serum (15 patients), 13 patients (87%) were HCV RNA positive. Similarly, HCV RNA was not detected in any of five anti-HCV-positive hemophiliac patients who were also positive for HBsAg, whereas 33 of 37 patients without HBV coinfection had detectable HCV RNA (126) . Whether viral interaction explains these findings is uncertain; experimental studies may provide answers in the future.
CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
In many patients, HCV infection results in progressive damage and the development of cirrhosis and its complications. However, patients with progressive liver disease may not be symptomatic, even when cirrhosis has developed. Furthermore, overall survival may not be altered by HCV infection acquired from transfusion (334) . Thus, in a follow-up study of patients prospectively diagnosed as having posttransfusion non-A, non-B hepatitis, survival was the same as in controls. There was a modest increase in liver disease-related mortality (total 3.3%; compared with 1.1 and 2% in two separate control populations). Alcohol was potentially a cofactor in this increase (334) . These data suggest that, in the majority of patients, HCV infection follows an indolent course. Similarly, when patients receiving organ transplants from anti-HCVpositive donors were monitored clinically, few developed significant liver disease (315) . In contrast, a subgroup of patients clearly had progressive disease and developed complications of chronic liver disease and hepatocellular carcinoma.
At the time of diagnosis, patients with chronic hepatitis C (abnormal aminotransferase levels during a 6-to 12-month period of observation and anti-HCV antibody positive) may have any of a range of abnormalities on liver biopsy (Fig. 7) . Thus, liver biopsy demonstrated chronic hepatitis in 50 to 90% and cirrhosis was present in 10 to 55% at the time of presentation with chronic hepatitis C infection (67, 71, 246, 260) . Longitudinal studies of patients with posttransfusion chronic disease indicate that chronic hepatitis is present on biopsy an average of 10 years after transfusion (range, 1 to 45 years), and cirrhosis is present by 20 years after (range, 10 to 50 years) (164 ity may be entirely dependent on the host response to the chronic infection.
In renal transplant recipients, chronic infection with HCV is common, being found in 28 of 100 U.S. patients (187), 22 of 120 Belgian patients (113) , and 23 of 151 (12%) patients in Hong Kong (50). An indolent or clinically silent course appears to be the usual finding (113, 187, 312, 316) , suggesting that chronic immunosuppression may decrease progression. However, poor outcome is observed in some patients (187) , and the length of follow-up in others (generally <10 years) may be insufficient for the development of complications from chronic liver disease. Whereas overall patient survival is unaffected by HCV infection (103, 187, 316) , reduced graft survival was noted in anti-HCV-positive black renal transplant patients with HCV infection in one study (103) and increased risk of infection and rejection were seen in another study (316) . Whether HCV will remain clinically silent in these immunosuppressed transplant recipients is yet to be determined.
HCV infection is associated with the development of hepatocellular carcinoma, as reported by a number of investigators (194, 355, 375, 422 ; reviewed in reference 310). As noted above, in patients with posttransfusion hepatitis monitored long term, hepatocellular carcinoma is a late occurrence, taking -30 years (range, 15 to 60 years) to develop (164) . At the time of initial presentation, hepatoma was infrequent in the United States and Europe but was found in up to 30% of Japanese patients (118, 260) . In a review of reports that determined the incidence of viral markers in 1,930 patients with hepatoma, HCV infection was present in 501 patients (26%) without HBV markers, in 221 patients (11%) with antibodies to hepatitis B viral markers, and in 177 patients (9%) with ongoing hepatitis B infection (310) . Thus, HCV infection potentially contributed to the development of hepatoma in 47% of the patients. Since neither second-generation assays nor HCV RNA was measured in every study, this is likely to be an underestimate of the importance of HCV in the development of hepatoma. A study of 91 U.S. patients with hepatocellular carcinoma, all negative for HBsAg, found serological or PCR positivity indicating HCV infection in 53 patients (58%), 14 of whom had evidence suggesting occult coinfection with HBV (204) . A lower incidence of HCV infection (14 of 87, 16%) was reported in another U.S. study (226) . Variation in incidence may reflect differences in viral, host, or environmental factors. Thus, hepatoma complicates chronic HCV infection, and HCV is the second most common etiologic agent in the development of this disease.
HCV AND OTHER DISEASES
Essential mixed cryoglobulinemia is strongly associated with HCV infection (3, 94, 95, 251; (70, 89, 129, 182) . In Italy, -80% of 74 patients had markers of HCV infection by EIA-2 and immunoblot assay (89) . In contrast, aplastic anemia following non-A, non-B hepatitis is not associated with HCV infection (79, 130, 289, 291) (328) . The previous practice of subdividing chronic hepatitis into chronic persistent and chronic active hepatitis is less useful in HCV infection than HBV infection (214) . None of the findings are pathognomonic for HCV infection, but some of the histological appearances are found more commonly with hepatitis C than in hepatitis due to other etiologic agents (17, 66, 197) . Direct comparison of hepatitis C with autoimmune chronic hepatitis has revealed histological features that are more often seen in one or the other disease (17) . The more indolent nature of hepatitis C in many patients, with relatively less aggressive disease and a lower incidence of cirrhosis, was apparent in the comparison. A histological pattern of mild chronic hepatitis with portal lymphoid follicles, mild fatty infiltration, and loss of bile ducts was the most common finding with HCV infection (17) . Three features more likely to be seen in HCV infection than in hepatitis B were identified by comparing biopsies from patients entered into two large treatment trials (197) . These were bile duct damage, lymphoid follicles, and large droplet fat. In addition, Mallory body-like material was seen only in HCV infection and not in HBV infection (197) . Specific patterns, while helpful in some patients, are neither unique nor universally present (66) .
HCV-infected cells in human liver have been identified immunohistochemically by using antibodies to the core, envelope, NS3, NS4, and NS5 regions of the HCV genome (26, 134, 323, 376) . Hepatocyte cytoplasmic staining was detected in liver tissue from 19 of 48 patients with core, envelope, and NS3 region antibodies (134) . Inflammation and fibrosis scores were higher in positive tissue. The HCV C100-3 antigen has also been detected in fresh frozen liver tissue from patients with acute and chronic infection, using indirect immunofluorescence (323) . In acute hepatitis, the majority of hepatocytes (50 to 70%) were reactive, whereas very low numbers of cells were positive in chronic hepatitis. In contrast, only reactivity to an antigen(s) encoded by the NS4 region was observed in formalin-fixed tissue by other investigators (26) . Most hepatocytes (60 to 90%) appeared positive, with variable intensity of the staining pattern. Antigens encoded by the E2, NS3, and NS5 regions were not detected (26) . The precise relationship between the expression of various viral antigens in hepatocytes and the progression of liver disease has not been established. TREATMENT Recombinant alpha interferon was approved for treatment of chronic hepatitis C following trials demonstrating sustained normalization of aminotransferase levels in -25% of U.S. patients after treatment with 3 x 106 U thrice weekly for 24 weeks (67, 73) . Beta interferon has also been tested for efficacy, particularly in Japan. An increase in sustained response rates to alpha interferon therapy may be achieved by increasing the treatment time from 24 weeks to 48 or 60 weeks (151, 209, 307, 325) . With an alternative regimen of 10 x 106 U six times a week for 2 weeks followed by three times a week for 12 weeks, sustained responses were observed in 48% (14 of 29) of Japanese patients (143) . However, besides the dose regimen, differences in the treated population compared with patients from other areas may account for the increased rate of response, since this magnitude of increase has not been observed by other investigators (209) . Improvement in pathology has been observed in some studies (224, 325) and, with regimens having improved efficacy, may be found more often in the future.
A number of investigators have reported that serum HCV RNA became undetectable or titers diminished in the patients responding to alpha interferon therapy (37, 53, 121, 221, 345, 347) . During relapse, serum HCV RNA once again emerged. Long-term follow-up has confirmed these findings in patients initially entered in pilot studies (347) . However, there are many exceptions to these observations, with patients achieving sustained normalization of hepatic aminotransferase levels despite re-emergence or persistence of serum HCV RNA (152, 190, 325) or relapsing despite continued loss of serum HCV RNA (170) . Measurement of HCV RNA in liver after therapy generally correlates with initial clinical outcome, with disappearance in all (109) or most (18) patients achieving sustained responses. HCV RNA in liver or serum can also decrease significantly without improvement in elevated aminotransferase levels (206) . Concomitantly with decreases in hepatic HCV RNA, HCV antigen detected by immunofluorescence staining may decrease in patients responding to interferon therapy (72) . Circulating anti-HCV antibodies may also fall in response to interferon therapy. Thus, antibody to C100-3 can become undetectable in responders during follow-up (325, 417) . In addition, titers of IgM anti-HCV core antibodies may reflect disease activity (258) . Thus far, however, there are no absolute measurements that can predict sustained responses.
Natural beta interferon has been tested in short-course therapy (intravenously for 4 weeks) for hepatitis C and non-A, non-B hepatitis in Japan (274, 278) . In an early pilot study, five of five patients with chronic posttransfusion non-A, non-B hepatitis responded initially, with decreases in aminotransferase levels, but there were no sustained responses (274 (6, 45, 236) . Response rates to alpha interferon therapy may also be adversely affected by increased hepatic iron (384) . The (253, 374) , alpha interferon subtype 2a (234) , and alpha interferon subtype 2b (132) . Lower titers of HCV RNA have been correlated with greater likelihood of a sustained response to natural alpha interferon (120, 253) , alpha interferon subtype 2b (132, 188, 222) , and beta interferon (171) . Pretreatment viral titer was more important in predicting response to beta interferon than was genotype (171) . In a group of six patients with chronic hepatitis C, there was heterogeneity in the hypervariable region sequence from the three individuals that did not respond to beta interferon therapy (276) . In contrast, the three patients who demonstrated a sustained response and clearance of HCV RNA from the circulation had little or no heterogeneity in the hypervariable region. Furthermore, in a small study of patients treated with alpha interferon, the mutation rate in the hypervariable region was higher in nonresponders (342) . Future evaluation of HCV-infected patients may include genotyping of the viral strain and assessment of homogeneity and mutation rates before selection for particular treatment protocols.
Patient Selection
Selection of patients with chronic hepatitis C for interferon therapy requires care and consideration. In occasional patients with features of autoimmunity, liver disease is exacerbated by alpha interferon (282, 346) . Occult, autoimmunity-related thyroid disease (229) and thrombocytopenia can become symptomatic, and severe exacerbation of lichen planus has been reported (298) . The observation of a high prevalence of thyroid autoantibodies (9 of 29 patients, 31%) in females with hepatitis C before interferon therapy and hypothyroidism in two patients before treatment and three other patients after treatment (371) (386) . In the second study, the results were similar: 13 treated patients (59%) and 6 controls (37%) had normal aminotransferase levels at 18-month follow-up (185) . However, HCV RNA was absent and aminotransferase levels were normal in seven treated patients (39%) but in none of the controls, suggesting the possibility of long-term quiescence. Additional studies of therapeutic regimens for acute disease are clearly needed.
Newer antiviral agents and combination therapies are undergoing testing. Ribavirin therapy decreased HCV RNA titers and normalized serum aminotransferase levels in treated patients; however, the response was not sustained (74, 308) . Ribavirin in combination with beta interferon has also been tested in pilot studies: unfortunately, without dramatic improvement in response rates (153) . In another preliminary study, alpha interferon in combined therapy with oral Nacetylcysteine improved aminotransferase levels in individuals previously unresponsive to alpha interferon alone (21) (215, 407) . HCV infection posttransplant can be newly acquired or a recurrent infection. When initially evaluated, the rate of HCV infection in liver transplant recipients was underestimated because few patients seroconverted for anti-HCV antibodies posttransplant and some lost preexisting antibody with immunosuppression (305, 408) . Studies using PCR to identify patients with HCV infection pretransplant and posttransplant have allowed better estimates of infection rates (172, 293, 408) . In 89 U.S. liver transplant patients with alcoholic or cryptogenic cirrhosis, HCV RNA was detected in 30 of 35 anti-HCV-positive patients and in 6 of 54 patients negative for anti-HCV (408) . In the posttransplant period, all of the patients with anti-HCV reactivity were viremic. In addition, four of six patients with detectable HCV RNA pretransplant but no anti-HCV antibodies were also viremic posttransplant. Another 17 patients had HCV RNA first detected posttransplant (408) . With better screening of blood and blood products, HCV infection acquired following liver transplantation should be less common in the future.
Whether immunosuppression also alters the relationship between the virus and host is less clear. Although viral titers are higher after liver transplantation (54), this does not always lead to hepatocyte damage. In studies from the United States (408) and Spain (215) , posttransplant hepatitis in the allograft was diagnosed in a mean of 51% of the patients with HCV RNA and was rare without evidence of HCV infection (Table  4) . Of note, however, a hepatitic pattern was not seen on liver biopsy in 49% of these immunosuppressed, viremic patients with HCV. In another study, HCV infection was detected by PCR in 15 of 25 (60%) patients with chronic hepatitis in an allograft; only 7 of the 15 (47%) patients were positive for anti-HCV antibodies (293) . Not all transplant programs have observed a high rate of persistent HCV infection after liver transplantation. Thus, HCV RNA was detected posttransplant in only 4 of 14 (29%) French patients who were previously anti-HCV positive (92) . Why the rate of persistent infection was so low in this group of patients, compared with others, has not been explained. In summary, hepatitis C after liver transplantation, as either a recurrence or a new infection, may be a frequent cause of chronic hepatitis and difficult to diagnose by conventional methods. However, the presence of persistent HCV infection posttransplant does not necessarily result in recurrent hepatitis. Long-term follow-up studies are needed to determine the importance of hepatitis C in the survival of liver transplant recipients.
PREVENTION OF INFECTION
By screening the blood supply (19, 77, 147) and by inactivating undetected virus (270) , it is hoped that future transmission of HCV by blood and blood products may be eliminated. Even products with currently low rates of hepatitis transmission, such as intravenous immune globulin, need to be monitored (377) . Introduction of tests for anti-HCV antibody detection has resulted in a decrease in the incidence of posttransfusion hepatitis (19, 77, 147, 361) . Furthermore, the low rate of posttransfusion hepatitis in countries like the United Kingdom and Sweden can be further decreased by the use of anti-HCV screening, without discarding too high a percentage of donations (63, 232) . Improvements in blood donor screening by direct questioning about medical history and social behavior have also contributed to the decrease in posttransfusion hepatitis (25) .
Postexposure prophylaxis recommendations for needle stick transmission are not uniform. Intramuscular immune serum globulin is prescribed by some (75, 108) (238) , as reported for influenza (378) . The lack of evidence for sustained clearance of the virus in the majority of humans or development of immunity to cross-challenge makes the task of vaccine formulation daunting. 
CONCLUSIONS

